Connect Biopharma (NASDAQ:CNTB) Price Target Cut to $5.00 by Analysts at BTIG Research

Connect Biopharma (NASDAQ:CNTB) had its price target cut by investment analysts at BTIG Research to $5.00 in a note issued to investors on Wednesday, Marketbeat Ratings reports. The firm presently has a “buy” rating on the stock. BTIG Research’s target price suggests a potential upside of 456.85% from the company’s previous close.

A number of other analysts have also weighed in on the company. Canaccord Genuity Group lowered their target price on Connect Biopharma from $7.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, September 16th. Oppenheimer lowered their target price on Connect Biopharma to $5.00 and set an “outperform” rating for the company in a report on Tuesday, September 22nd. Weiss Ratings upgraded Connect Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 24th. HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Connect Biopharma in a report on Monday, September 14th. Finally, Piper Sandler initiated coverage on Connect Biopharma in a report on Friday, June 26th. They set an “overweight” rating and a $7.00 price objective for the company. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $6.14.

Connect Biopharma Stock Down 3.1%

Connect Biopharma stock opened at $0.90 on Wednesday. The business has a fifty day moving average of $1.87 and a two-hundred day moving average of $2.26. The company has a quick ratio of 2.37, a current ratio of 2.37 and a debt-to-equity ratio of 0.01. The firm has a market cap of $56.54 million, a P/E ratio of -0.75 and a beta of -0.16. Connect Biopharma has a twelve month low of $0.89 and a twelve month high of $3.82.

Connect Biopharma (NASDAQ:CNTB) last posted its earnings results on Wednesday, August 12th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.04. The company had revenue of $2.75 million for the quarter, compared to analysts’ expectations of $0.74 million. On average, analysts forecast that Connect Biopharma will post -1.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Connect Biopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE purchased a new position in Connect Biopharma in the 1st quarter worth $41,000. ADAR1 Capital Management LLC purchased a new position in Connect Biopharma in the 1st quarter worth $1,945,000. Knott David M Jr raised its stake in Connect Biopharma by 93.9% in the 1st quarter. Knott David M Jr now owns 387,835 shares of the company’s stock worth $1,016,000 after acquiring an additional 187,835 shares during the last quarter. Simplify Asset Management Inc. acquired a new stake in Connect Biopharma during the 1st quarter worth about $135,000. Finally, Richmond Brothers Inc. acquired a new stake in Connect Biopharma during the 4th quarter worth about $489,000. Hedge funds and other institutional investors own 58.72% of the company’s stock.

Key Stories Impacting Connect Biopharma

Here are the key news stories impacting Connect Biopharma this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and raised its FY2026 EPS forecast modestly to a loss of $1.17 from a loss of $1.19. The firm also improved its FY2027 estimate to a loss of $0.67 from a loss of $1.03, suggesting expectations for somewhat lower losses in that year. HC Wainwright Issues Pessimistic Outlook for CNTB Earnings
• Neutral Sentiment: HC Wainwright increased its Q4 2026 EPS estimate to a loss of $0.25 from a loss of $0.28, but still expects CNTB to remain unprofitable. The firm forecasts a Q3 2026 loss of $0.32 per share, compared with the current full-year consensus estimate of a $1.10 loss.
• Neutral Sentiment: A separate report compared Connect Biopharma with Inhibrx Biosciences, but the provided information does not identify a new operational, clinical, or financial catalyst for CNTB. Financial Contrast: Connect Biopharma and Inhibrx Biosciences
• Negative Sentiment: HC Wainwright lowered its longer-term EPS estimates for FY2028, FY2029 and FY2030 to losses of $0.94, $1.10 and $1.16, respectively. The FY2030 forecast was sharply reduced from a loss of $0.10, while the FY2029 estimate fell from a loss of $0.50, signaling substantially weaker long-term earnings expectations.
• Negative Sentiment: The firm also reduced its Q3 2026 EPS forecast to a loss of $0.32 from $0.30. Although HC Wainwright remains bullish overall, the combination of near-term losses and materially weaker long-range forecasts likely explains the negative investor reaction.

Connect Biopharma Company Profile

Connect Biopharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic inflammatory diseases driven by T-cell activity. The company uses its drug-discovery platform to identify and advance small-molecule and antibody-based treatments intended to selectively regulate immune responses while limiting broader immunosuppression.

Its pipeline has included ropsacitinib, formerly known as CBP-307, an oral selective sphingosine-1-phosphate receptor 1 modulator investigated for inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease.